Neuroprotection in the complex treatment of primary glaucoma
https://doi.org/10.53432/2078-4104-2023-22-2-55-61
Abstract
Neuroprotection is a direction in therapy that prevents the loss of neurons due to external factors. In glaucoma, the use of both direct and indirect neuroprotection is pathogenetically justified, which, respectively, can have a direct protective effect on retinal ganglion cells, or affect various risk factors for the development of neuropathy. At present, Retinalamin — a complex of peptides isolated from cattle retinas — is used in ophthalmology for neuroprotective purposes. Although the clinical efficacy and safety of Retinalamin is well established, its exact mechanism of action remains unclear. To amend this, in vitro studies of its cytotoxicity and efficacy were carried out, as well as a comparison of its effectiveness in various ways of administration, and a retrospective analysis of its use.
About the Authors
S. E. Avetisov
Krasnov Research Institute of Eye Diseases; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Academician of the Russian Academy of Sciences, Professor, Scientific Director; Head of the Academic Department of Eye Diseases
11A Rossolimo St., Moscow, 119021
8-2 Trubetskaya St., Moscow, 119991
A. N. Volzhanin
Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Sci. (Med.), junior researcher at the Department of Glacuoma
11A Rossolimo St., Moscow, 119021
I. A. Kozlova
Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Sci. (Med.), senior researcher at the Department of Glaucoma
11A Rossolimo St., Moscow, 119021
References
1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global Health 2021; 9(2):144-160.
2. Egorov Е.A., Egorоva T.E., Shramko Yu.G. Effect of Retinalamin usage in patients with compensated primary open-angle glaucoma. RMJ Clinical Ophthalmology 2014; 14(4):188-193.
3. Astakhov Yu.S., Butin E.V., Morozova N.V., Sokolov V.O. Results of retinalamin usage in patients with primary open-angle glaucoma. Glaukoma 2006; 2:43-47.
4. Mazunin I.Yu. Results of Retinalamin neuroretinaprotector usage after laser trabeculoplasty in compensated primary open-angle glaucoma treatment. Meditsinskiy Almanakh 2014; 1 (31):69-73.
5. Malishevskaya T.N., Dolgova J.G. Comparative effectiveness analysis of different methods of neuroprotective therapy in patients with nonprogressive advanced primary glaucoma. Natsional’nyi zhurnal glaucoma 2016; 15(2):84-92.
6. Gabashvili A.N., Erichev V.P., Nesterova T.N., Subbot A.M. Retinal ganglion cells: potentiality for neuroprotective glaucoma treatment. Natsional’nyi zhurnal glaucoma 2017; 16(2):74-81.
7. Bunin A.Ya., Bibidzhaev M.A., Suprun A.V. On the participation of lipid peroxidation in the destruction of the drainage system of the eyes in open-angle glaucoma. Vestnik oftal’mologii 1984; 2:13-16.
8. Erichev V.P., Shamshinova A.M., Lovpazhe D.N., Egorova I.V., Kolomoitseva E.M. Comparative evaluation of the neuroprotective effect of peptide bioregulators in patients with different stages of primary open-angle glaucoma. Glaukoma 2005; 1:18-24.
9. Kurysheva N.I., Vinetskaya M.I., Erichev V.P., Demchuk M.L. The role of free-radical reactions of aqueous humor in the development of primary open-angle glaucoma. Vestnik oftal’mologii 1996; 4:3-5.
10. Kurysheva N.I., Erichev V.P., Vinetskaya M.I. On the permeabilityof blood-aqueous barrier in primary open-angle glaucoma. Vestnik oftal’mologii 1998; 1:10-13.
11. Kurysheva N.I., Aseychev A.V. Study of antiradical activity of modern glaucoma medications considering their neuroprotective action. Glaukoma 2004; 4:6-10.
12. Kurysheva N.I., Azizova O.A., Piryazev A.P. Antiradical and antioxidant activity of carbonic anhydrase inhibitors for topical treatment of glaucoma. Russian ophthalmological journal 2011; 4(3):55-61.
13. Poznyak N.I., Kovshel I.L., Grigorovich I.L. et al. Blockers of calcium channels in treatment of primary open-angle glaucoma. Vestnik oftal’mologii 1998; 3:5-6.
14. Egorov E.A., Davydova N.G., Romanenko I.A. et al. Mexidol in a complex treatment of glaucoma. RMJ Clinical Ophthalmology 2011; 12(3):107-109.
15. Alekseev V.N., Morozova N.V. Retinalamin usage in patients with primary open-angle glaucoma. Glaukoma 2013; 1:49-52.
16. Melena J, Stanton D, Osborne NN. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch Clin Exp Ophthalmol 2001; 239:522-530.
Review
For citations:
Avetisov S.E., Volzhanin A.N., Kozlova I.A. Neuroprotection in the complex treatment of primary glaucoma. National Journal glaucoma. 2023;22(2):55-61. (In Russ.) https://doi.org/10.53432/2078-4104-2023-22-2-55-61
Views:
485
Email this article 